HIV vaccine being tested in SpainPublished On: Thu, Sep 29th, 2011 | Virology | By BioNews
A team of Spanish researchers has developed a prototype of a vaccine against the AIDS-causing HIV virus that is “much more powerful” than those made to date.
The feat was made public Wednesday at a press conference by those responsible for the research — Mariano Esteban, of the National Biotechnology Center of Spain’s CSIC research council; Felipe Garcia, with Barcelona’s Clinic Hospital; and Juan Carlos Lopez Bernaldo de Quiros, with Madrid’s Gregorio Maranon Hospital.
After showing a high level of efficiency in mice and monkeys, testing was begun in humans a year ago and during the first phase the vaccine was administered to 30 healthy people selected from among 370 volunteers.
The study was “random and double blind”, that is to say that researchers did not decide which subjects would receive the vaccine and which would receive the placebo, and the people in the study also did not know which one they were receiving, said Lopez Bernaldo de Quiros.
Six people received the placebo and 24 the vaccine. The latter experienced “limited” and “slight” secondary effects (headaches, pain in the injection area or general discomfort), and so it can be confirmed that “the vaccine is safe for continuing with the clinical development of the product”, the researcher said.
Ninety-five percent of the patients who received the vaccine developed bodily defenses – although the normal rate for prior HIV vaccines has been 25 percent – and also, whereas other vaccines stimulate the production of cells or antibodies, this prototype “managed to stimulate both”, Felipe Garcia emphasized.
In 85 percent of the patients, the defenses generated were maintained for at least a year, “which in this field is enough time,” he added.
The researchers will now perform a new clinical trial, this time with volunteers infected with HIV, with the aim of learning if the vaccine, in addition to preventing AIDS can also be used to treat it.
The vaccine prototype, patented by the CSIC, is designed to combat HIV’s subtype B, the one that is most prevalent in Europe, the US, South and Central America and the Caribbean. The strain that is most widely spread in Africa and Asia is subtype C.